Acoltremon for Dry Eye

This trial tests whether a new eye drop, acoltremon 0.003%, can help individuals with Stage 1 Neurotrophic Keratopathy, a condition causing dry eyes due to nerve damage. The goal is to determine if the eye drop increases tear production and improves eye health. Suitable participants have a diagnosis of this specific eye condition, along with reduced corneal sensation and dry eyes. Participants should not have eye infections or recent eye surgeries and must be able to discontinue other eye medications during the trial. As a Phase 4 trial, this research aims to understand how this already FDA-approved and effective treatment can benefit more patients.

Yes, you will need to stop using any topical eye medications 8 days before the study starts and avoid using artificial tears 2 hours before your first visit. You must stay off these medications for the entire study.

Research has shown that acoltremon eye drops (0.003%) are generally safe for use. Past studies found no major safety issues, meaning users did not experience significant negative side effects. The FDA has approved this treatment for dry eye disease, indicating it is well-tolerated. Additionally, no important safety differences exist between older and younger users of acoltremon. Overall, the evidence supports acoltremon as a safe choice for managing dry eye symptoms.¹²³⁴⁵

Unlike the standard of care for dry eye, which often includes artificial tears or anti-inflammatory drops, Acoltremon Ophthalmic Solution 0.003% offers a fresh approach by using a unique active ingredient. This treatment targets the root cause of dry eye by enhancing natural tear production rather than simply providing temporary relief. Researchers are excited about Acoltremon because it has the potential to offer longer-lasting benefits and improve overall eye health, setting it apart from existing therapies that only address symptoms.

Research has shown that Acoltremon Eye Drops 0.003% help treat dry eye by increasing natural tear production. Studies found that it significantly improves tear production and reduces dry eye symptoms. In two important studies, patients reported better results than those using a placebo. Improvements appeared quickly and persisted over time. The treatment is approved for dry eye, confirming its effectiveness.²⁵⁶⁷⁸